The pattern of inhibited/induced transactivation observed for the effects of these dual NR4A1/2 ligands in RKO cells was also observed in SW480 (Figure 3B) and HCT116 (Figure 3C) colon cancer cell lines and confirms that the CDIM compounds target both NR4A1 and NR4A2 in transactivation assays using GAL4-receptor chimeras but with inverse induction responses in colon cancer cells. Here, NR4A2 is linked to malignant colon neoplasm.